Ovid Therapeutics Inc. Annual Share-based Payment Arrangement, Expense in USD from 2015 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Ovid Therapeutics Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2015 to 2023.
  • Ovid Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $1.31M, a 19.8% decline year-over-year.
  • Ovid Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $6.81M, a 5.79% decline year-over-year.
  • Ovid Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $7.29M, a 11.1% increase from 2022.
  • Ovid Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $6.56M, a 29.7% increase from 2021.
  • Ovid Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2021 was $5.05M, a 32.8% decline from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $7.29M +$729K +11.1% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-08
2022 $6.56M +$1.5M +29.7% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-08
2021 $5.05M -$2.47M -32.8% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-13
2020 $7.53M +$2.32M +44.6% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-15
2019 $5.21M -$1.86M -26.3% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-15
2018 $7.06M +$666K +10.4% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-11
2017 $6.4M +$2.76M +75.7% Jan 1, 2017 Dec 31, 2017 10-K 2019-03-07
2016 $3.64M +$2.18M +150% Jan 1, 2016 Dec 31, 2016 10-K 2018-03-29
2015 $1.46M Jan 1, 2015 Dec 31, 2015 10-K 2018-03-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.